Table 1.

Baseline characteristics of Women’s Health Initiative Participants who consented to extended follow-up after enrollment in the Hormone Therapy Estrogen-Alone Trial (April 2005)

	Active		Placebo		P-Value1
	N=3778	%	N=3867	%
Age group at screening					0.88
50–59	1223	32.4	1232	31.9
60–69	1740	46.1	1799	46.5
70–79	815	21.6	836	21.6
Race/ethnicity					0.27
White	2945	78.0	3001	77.6
Black	514	13.6	565	14.6
Hispanic	189	5.0	181	4.7
American Indian	31	0.8	18	0.5
Asian/Pacific Islander	54	1.4	49	1.3
Unknown	45	1.2	53	1.4
HRT use status					0.43
Never used	1929	51.1	1916	49.6
Past user	1304	34.5	1373	35.5
Current user	544	14.4	575	14.9
HT Duration					0.52
< 5 years	960	51.9	1036	53.1
5 – 10 years	348	18.8	377	19.3
≥ 10 years	541	29.3	538	27.6
Body-mass index (kg/m2), baseline					0.21
< 25	785	20.9	771	20.1
25 – < 30	1289	34.3	1391	36.2
≥ 30	1687	44.9	1683	43.8
Smoking status					0.30
Never	1988	53.1	1972	51.5
Past	1417	37.9	1489	38.9
Current	336	9.0	370	9.7
Parity					0.04
Never pregnant/Never had term pregnancy	350	9.3	307	8.0
≥1 term pregnancy	3400	90.7	3539	92.0
Age at first birth, y					0.53
<20	822	27.0	872	27.3
20 – 29	2060	67.7	2128	66.7
30+	163	5.4	190	6.0
Hysterectomy age group					0.17
<40	1495	39.8	1501	39.0
40–49	1643	43.7	1662	43.2
50–54	345	9.2	412	10.7
55+	275	7.3	271	7.0
Bilateral oophorectomy	1370	39.0	1507	41.8	0.01
Treated diabetes (pills or shots)	243	6.4	250	6.5	0.95
Hypertensive (Self-report or high BP)	1806	51.1	1844	51.2	0.92
History of high cholesterol requiring pills	490	14.3	536	15.5	0.16
Statin group	288	7.6	302	7.8	0.76
Aspirin use >=80 mg for at least 30 days	712	18.8	784	20.3	0.12
History of angina	243	6.5	253	6.6	0.82
History of CABG/PTCA	69	1.9	70	1.8	0.96
Stroke ever	51	1.3	47	1.2	0.60
History of DVT or PE	65	1.7	60	1.6	0.56
History of fracture age 55+	455	16.5	447	15.8	0.51
Times fell down last 12 months					0.16
None	2368	67.5	2331	65.2
1 time	680	19.4	722	20.2
2 times	296	8.4	346	9.7
3 or more times	164	4.7	174	4.9

¹Test of association.